NCT01978548View on ClinicalTrials.gov

A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Alzheimer Disease
Interventions
DRUG

JNJ-54861911 10 mg

JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.

DRUG

JNJ-54861911 50 mg

JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.

DRUG

Placebo

Matching placebo will be administered as 2 oral tablets once daily.

Trial Locations (10)

Unknown

Antwerp

Ghent

Hoboken

Amsterdam

Barcelona

Madrid

Terrassa

Valencia

Mölndal

Stockholm

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01978548 - A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease | Biotech Hunter | Biotech Hunter